Description: Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development, and manufacturing of oral dose forms for prescription and consumer health products. This segment's oral dose forms include softgel, modified release technologies, and immediate release solid oral products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. This segment also offers analytical chemical and cell-based testing and scientific services, stability testing, respiratory products formulation and manufacturing, regulatory consulting, and bioanalytical testing for biologic products. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.
Home Page: www.catalent.com
CTLT Technical Analysis
14 Schoolhouse Road
Somerset,
NJ
08873
United States
Phone:
732 537 6200
Officers
Name | Title |
---|---|
Mr. John R. Chiminski | Exec. Chair of the Board |
Mr. Alessandro Maselli | CEO & Director |
Mr. Thomas P. Castellano | Sr. VP & CFO |
Mr. Steven L. Fasman Esq. | Exec. VP, Corp. Sec. & Chief Admin. Officer |
Dr. Aristippos Gennadios Ph.D. | Group Pres of Pharma & Consumer Health Segment |
Mr. Ricky Hopson | Pres & Division Head for Clinical Devel. and Supply |
Ms. Karen Murphy Santiago | VP & Chief Accounting Office |
Mr. Julien Meissonnier | VP & Chief Scientific Officer |
Mr. Charles Lickfold | Sr. VP & Chief Information Officer |
Mr. Paul Surdez | VP of Investor Relations |
Exchange: NYSE
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Pharmaceuticals |
GIC Sub-Industry: | Pharmaceuticals |
Forward PE: | 13.1926 |
---|---|
Trailing PE: | 20.5705 |
Price-to-Book MRQ: | 1.7713 |
Price-to-Sales TTM: | 1.6504 |
IPO Date: | 2014-07-31 |
Fiscal Year End: | June |
Full Time Employees: | 19000 |